Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase I
Allopregnanolone 再生治疗 MCI/AD:剂量探索 I 期
基本信息
- 批准号:8605469
- 负责人:
- 金额:$ 242.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-20 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAllopregnanoloneAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmendmentAmericanAmyloidAmyloid beta-ProteinAnimalsBiological MarkersBlood - brain barrier anatomyBrainCell ProliferationCholesterol HomeostasisChronicClinicalClinical ResearchClinical TrialsClinical trial protocol documentCognitionCognitiveCollaborationsCommitDataDevelopmentDiagnosisDiseaseDisease ProgressionDoseDrug ContainersDrug FormulationsDrug KineticsEventFDA approvedFoundationsFutureGenerationsGoalsHemorrhageHippocampus (Brain)HumanImageIncidenceInflammationInflammatory ResponseInterventionInvestigational DrugsInvestigational New Drug ApplicationLettersMagnetic Resonance ImagingMaximum Tolerated DoseMedicalMethodsMolecular WeightMusMyelinNatural regenerationNatureNeurologyNeuronsOutcomeParticipantPathologyPathway interactionsPhasePlacebosRegenerative MedicineRegimenResearch PersonnelRestRiskSafetySeveritiesSuggestionSymptomsSystemSystems BiologyTherapeuticTranslational ResearchTraumatic Brain InjuryTreatment Efficacyagedbasecognitive functiondesignefficacy trialmeetingsmultidisciplinarynerve stem cellneurogenesisneurosteroidsphase 2 studypre-clinicalpreventpublic health relevanceregenerativerelating to nervous systemrestorationsmall moleculestemtherapeutic targettraffickingwhite matter
项目摘要
DESCRIPTION: Therapeutics to prevent, delay and treat Alzheimer's disease (AD) remains to be achieved. Currently, over 5 million Americans are diagnosed with AD and the number is projected to increase to 11-16 million within two decades unless therapeutic advances are made. Proposed herein is a regenerative medicine, systems biology approach that targets the regenerative system of the brain while simultaneously activating systems to reduce AD pathology. Allopregnanolone (Allo) is a pleiotropic regenerative therapeutic that promotes neurogenesis and restores cognitive function in both a preclinical AD model and wild type aged mice and reduces pathology in a preclinical AD model. Further Allo promotes regeneration of human neural stem cells. Allo is a neurosteroid endogenous to the brain of low molecular weight and blood brain barrier penetrant with abundant existing safety data in animals and humans. Its mechanisms of neural stem cell proliferation and restoration of cognitive function are well characterized and consistent with well-described neurogenic mechanisms in brain. Allo reduces AD pathology via well-established pathways upstream to Abeta generation to prevent the generation of Abeta while also decreasing inflammation and increasing myelin generation. Based on a foundation of preclinical discovery (ADDF), translational research (NIA U01), clinical development with NIA USC ADRC and FDA assessment, we propose a Phase 1 multiple ascending dose clinical trial of four Allo doses administered in a regenerative regimen of once-per-week for twelve weeks to establish a safe and tolerated dose of Allo necessary to advance to a Phase 2 efficacy trial. To achieve this goal, two specific aims are proposed. Aim 1 is designed to conduct a Phase 1 multiple ascending dose trial of Allo in participants diagnosed with MCI due to AD and early AD. Primary safety objectives are to determine: 1) maximally tolerated dose; 2) incidence and severity of treatment emergent adverse events; 3) designated medical events; 4) clinically important changes in safety assessments including amyloid related imaging abnormalities (ARIA). Aim 2 is designed to conduct exploratory safety and feasibility analyses regarding the effect of once- per-week-exposure for 12 weeks to Allo at 4 doses on cognitive function and MRI-based biomarkers. Secondary objectives are to: 1) assess potential short-term effects of Allo dosing on cognition and MRI indicators of AD; 2) inform subsequent phase 2 proof of concept trial with MRI-based biomarkers of regenerative efficacy. A multidisciplinary team of investigators with expertise in Allo systems biology and translational research and clinical trials for AD therapeutics are committed to the project. Trial outcomes will provide: 1) an estimated safe and well-tolerated dose of Allo; 2) parameter estimates for cognitive efficacy to advance to a Phase 2 proof of concept trial of Allo; and 3) parameter estimates for MRI-based biomarkers. This proposal meets the objectives of RFA-AG-13-016.
描述:预防,延迟和治疗阿尔茨海默病(AD)的治疗方法仍有待实现。目前,超过500万美国人被诊断患有AD,除非治疗取得进展,否则预计这一数字将在二十年内增加到1100万至1600万。本文提出了一种再生医学、系统生物学方法,其靶向脑的再生系统,同时激活系统以减少AD病理。别孕烯醇酮(Allo)是一种多效性再生治疗剂,其在临床前AD模型和野生型老年小鼠中促进神经发生并恢复认知功能,并在临床前AD模型中减少病理学。此外,Allo促进人类神经干细胞的再生。Allo是一种低分子量的脑内源性神经甾体,具有血脑屏障渗透性,在动物和人体中已有丰富的安全性数据。它的神经干细胞增殖和恢复认知功能的机制是很好的特点,并与脑中的神经发生机制的描述一致。Allo通过Abeta生成上游的成熟途径减少AD病理学,以防止Abeta的生成,同时还减少炎症和增加髓鞘生成。基于临床前发现(ADDF)、转化研究(NIA U 01)、NIA USC ADRC临床开发和FDA评估的基础,我们提出了一项1期多剂量递增临床试验,以每周一次的再生方案给予4种Allo剂量,持续12周,以确定进入2期疗效试验所需的安全和耐受剂量。为实现这一目标,提出了两个具体目标。目的1是在诊断为AD和早期AD所致MCI的受试者中进行Allo的I期多次递增剂量试验。主要安全性目的是确定:1)最大耐受剂量; 2)治疗后出现的不良事件的发生率和严重程度; 3)指定的医学事件; 4)安全性评估中具有临床意义的变化,包括淀粉样蛋白相关成像异常(ARIA)。目的2旨在进行探索性安全性和可行性分析,分析每周一次暴露于4种剂量的Allo 12周对认知功能和基于MRI的生物标志物的影响。次要目的是:1)评估Allo给药对AD的认知和MRI指标的潜在短期影响; 2)为后续的II期概念验证试验提供信息,该试验使用基于MRI的再生功效生物标志物。一个多学科的研究人员团队,具有Allo系统生物学和AD治疗的转化研究和临床试验的专业知识,致力于该项目。试验结果将提供:1)估计的Allo的安全和良好耐受剂量; 2)用于认知功效的参数估计,以推进到Allo的概念试验的2期验证;和3)用于基于MRI的生物标志物的参数估计。本提案符合RFA-AG-13-016的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERTA EILEEN BRINTON其他文献
ROBERTA EILEEN BRINTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERTA EILEEN BRINTON', 18)}}的其他基金
Translational Research in Alzheimer's Disease and related Dementias (TRADD)
阿尔茨海默病和相关痴呆症的转化研究 (TRADD)
- 批准号:
10709167 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
Allopregnanolone 的新型鼻内制剂,一种阿尔茨海默病的再生疗法
- 批准号:
10698555 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10560591 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10547639 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
PhytoSERM 预防更年期相关脑代谢和认知能力下降的功效:双盲、随机、安慰剂对照 2 期临床试验
- 批准号:
10344556 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
PhytoSERM 针对更年期潮热和持续大脑健康
- 批准号:
10707107 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10689308 - 财政年份:2021
- 资助金额:
$ 242.96万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10491851 - 财政年份:2021
- 资助金额:
$ 242.96万 - 项目类别:
Regulatory and Human Study Operations (RHSO) Core C
监管和人体研究运营 (RHSO) 核心 C
- 批准号:
10270190 - 财政年份:2021
- 资助金额:
$ 242.96万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 242.96万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 242.96万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 242.96万 - 项目类别: